Author:
SHIGA Tsuyoshi,HASHIGUCHI Masayuki,NAKAMURA Koichi,SHIMIZU Mikiko,SHIMIZU Kaoru,SUZUKI Atsushi,MOCHIZUKI Mayumi,HAGIWARA Nobuhisa
Publisher
Japanese Society of Clinical Pharmacology and Therapeutics
Subject
Pharmacology (medical),Pharmacology
Reference20 articles.
1. 1) Hattori Y, Hidaka T, Aisaka K, Satoh F, Ishihara T. Effects of SUN 1165, a new potent antiarrhythmic agent, on the kinetics of rate-dependent block of Na channels and ventricular conduction of extrasystoles. J Cardiovasc Pharmacol. 1988; 11(4): 407-12.
2. 2) Aisaka K, Hidaka T, Inomata N, Hamasaki S, Ishihara T, Morita M. N-(2,6-dimethylphenyl)-8-pyrrolizidine acetamide hydrochloride hemihydrate (SUN 1165): a new potent and long-acting antiarrhythmic agent. Arzneimittelforschung. 1985; 35(8): 1239-45.
3. 3) Atarashi H, Inoue H, Hiejima K, Hayakawa H, for the PSTAF Investigators. Conversion of recent-onset atrial fibrillation by a single oral dose of pilsicainide (Pilsicainide Suppression Trial on Atrial Fibrillation). Am J Cardiol. 1996; 78(6): 694-7.
4. 4) Okishige K, Nishizaki M, Azegami K, Igawa M, Yamawaki N, Aonuma K. Pilsicainide for conversion and maintenance of sinus rhythm in chronic atrial fibrillation: a placebo-controlled, multicenter study. Am Heart J. 2000; 140(3): e13.
5. 5) Komatsu T, Sato Y, Tachibana H, Nakamura M, Horiuchi D, Okumura K. Randomized crossover study of the long-term effects of pilsicainide and cibenzoline in preventing recurrence of symptomatic paroxysmal atrial fibrillation: influence of the duration of arrhythmia before therapy. Circ J. 2006; 70(6): 667-72.